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Background: Terminal deletions of chromosome 4q are associated with a broad spectrum of phenotypes including
cardiac, craniofacial, digital, and cognitive impairment. The rarity of this syndrome renders genotype-phenotype
correlation difficult, which is further complicated by the widely different phenotypes observed in patients sharing
similar deletion intervals.
Case presentation: Herein, we describe a boy with congenital hearing impairment and a variety of moderate
syndromic features that prompted SNP array analysis disclosing a heterozygous 6.9 Mb deletion in the 4q35.1q35.2
region, which emerged de novo in the maternal germ line.
Conclusion: In addition to the index patient, we review 35 cases from the literature and DECIPHER database to
attempt genotype-phenotype correlations for a syndrome with great phenotypic variability. We delineate intervals
with recurrent phenotypic overlap, particularly for cleft palate, congenital heart defect, intellectual disability, and
autism spectrum disorder. Broad phenotypic presentation of the terminal 4q deletion syndrome is consistent with
incomplete penetrance of the individual symptoms.
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Terminal deletions of chromosome 4q are a rare event
with an approximate incidence of 1 in 100,000 [1,2]. While
the majority are de novo cases, an estimated 10-20% are
the unbalanced product of a parental reciprocal transloca-
tion. Furthermore, some pediatric cases with classical phe-
notypes have inherited their 4q deletion from a parent
described as either normal or only mildly affected [3-6]. Al-
though there is a high degree of phenotypic variation in
those presenting overlapping deletion intervals, there is a
general consensus that chromosome 4q deletion syndrome
is characterized by intellectual disability (ID), craniofacial
dysmorphism, rotated or low-set ears, cleft palate (CP),
micrognathia, congenital heart defects (CHD), craniofacial,* Correspondence: thomas.haaf@uni-wuerzburg.de
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unless otherwise stated.skeletal and digital abnormalities, and occasionally autism
spectrum disorder (ASD), behavioural disorders, and de-
velopmental delay [7-9]. Chromosome 4q deletions are
divided in two different subgroups depending on the re-
gion of 4q that is deleted: interstitial, spanning the centro-
mere through 4q28.3 and terminal, from 4q31.1 to 4qter.
Although both deletion types each have highly variable
phenotypic associations, terminal deletion cases present a
broader phenotypic range including CHD, craniofacial and
skeletal abnormalities. The 4q33 region has been proposed
as critical for ulnar deficiency, cleft lip and palate, and
brain development [10].
Herein, we report on an eight year-old boy with mod-
erate dysmorphic features and a de novo deletion in the
4q35.1q35.2 region. By analyzing the considerable pheno-
typic variability of terminal 4q deletion cases from the lit-
erature and DECIPHER database, we attempt to delineate
critical intervals for common phenotypic features.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Clinical report
The proband is the only child of two healthy unrelated
parents of German ethnicity, born at a gestational age
of 38.3 weeks, after an uncomplicated pregnancy and
normal spontaneous delivery. Birth weight was 3,125 g
(25th centile), APGAR scores of nine and ten at one
and five minutes, respectively, cord blood pH was 7.3,
and an unremarkable otoacoustic emissions newborn
hearing screening test was recorded. At four months
of age, he had bilateral hearing impairment in the
60 dB range and was fitted with hearing aids. We se-
quenced genes commonly screened for hearing loss,
including GJB2 (MIM: 121011), GJB3 (MIM: 603324),
and GJB6 (MIM: 604418). Sequencing disclosed a het-
erozygous mutation in GJB3 c.94C > T, p.Arg32Trp
(rs1805063; minor allele frequency T = 0.015), which is
a well-described autosomal recessive deafness gene re-
quiring a second heterozygous mutation either in trans
or in compound heterozygous configuration to convey
hearing loss. A targeted deafness gene next generation
sequencing panel was negative for other pathogenic
mutations.
In the first year of life, he was diagnosed with aortic isth-
mus stenosis, corrected via balloon angioplasty, and a
patent foramen ovale. He demonstrated shortened PQ
intervals on an electrocardiogram indicative of an atrio-
ventricular node irregularity. Regular pediatric cardiology
follow-up was recommended. He also presented with
chronic Eustachian tube dysfunction that was treated sev-
eral times with myringotomy tubes, as well as a bifid
uvula. In the fifth year of life, a submucous CP was de-
tected. During the same year, he underwent corrective
surgery for the CP and velopharyngeal insufficiency. Add-
itionally, he presented with bilateral cryptorchidism that
required testicular orchiopexie. An abdominal sonogram
could not rule out the possibility of a left duplex kidney;
urine analysis was within normal limits. Despite a small
thyroid, he had normal thyroid function on lab testing.
His blood profile was unremarkable apart from mild con-
current deficiencies of blood coagulation factors IX (56%),
XI (48%) and XII (38%). He had an elevated prothrombin
time of 46.5 s (normal: 25–39 s) and an elevated lupus
anticoagulant confirmatory test of 1.26 (normal: 0.91-
1.07). Further coagulation testing was negative for von
Willebrand disease.
Psychological developmental evaluation at the age of
three to four years showed mild general developmental
delay (six months). Subsequent evaluations showed nor-
mal development. Neurological evaluation at the age
five showed a lack of age-appropriate coordination. He
also had delayed speech and language development,
likely secondary, at least in part, to his hearing impair-
ment and extensive hospitalization history. Currently,he attends regular school and does not require remedial
classroom instruction.
Methods
Classical cytogenetic and fluorescence in situ hybridization
(FISH) analyses
Chromosomes of the proband and his parents were pre-
pared from peripheral blood lymphocyte cultures and
analyzed by GTG-banding at the 500 band resolution.
FISH was carried out using selected BAC probes from
the deleted region. BAC DNA was labelled by nick trans-
location with fluorescein-12-dUTP (Roche Diagnostics,
Mannheim, Germany) or tetramethyl-rhodamine-5-dUTP
(Roche), and hybridized overnight to denatured chromo-
somes. Image acquisition and analysis were performed
using FISHView 2.0 software (Applied Spectral Imaging,
Edingen-Neckarhausen, Germany).
Copy number variation and genotype analyses
Genomic DNA (gDNA) of the proband and his parents
was prepared from peripheral blood by standard salt ex-
traction method. The Illumina Omni1-Quad v1.0 SNP
array (Illumina, San Diego, CA, USA), with >1.1 million
SNP markers, was used for whole genome genotyping
and copy number variation (CNV) detection. 200 ng
gDNA were utilized in an Illumina Infinium HD Ultra
Assay according to the manufacturer’s specifications.
Data were analyzed using GenomeStudio (v2011.1) soft-
ware with both cnvPartition 3.2.0 (Illumina) and Quan-
tiSNP 2.2 copy number algorithm [11]. Genotypes of
father, mother and proband were obtained from the SNP
array for parent-of-origin determination. HaploPainter
[12] was used in combination with manual intervention
to illustrate the absence of maternal genotypes in the de-
letion patient. The terminal 4q monosomy was validated
by real-time quantitative polymerase chain reaction
(qPCR) of FRG1 exons 1, 8, and DUX4L6 using the Sen-
siMix SYBR Green kit (Bioline, Luckenwalde, Germany).
Mapping critical intervals for terminal 4q deletion
syndrome phenotypes
This study makes use of data generated by the DECIPHER
consortium, which is funded by the Wellcome Trust (http://
decipher.sanger.ac.uk). With the combined DECIPHER
cases (nos. 278055, 248967, 249192, 249458, 249476,
249536, 249541, 249655, 251175, 253743, 254882, 256186,
257358, 264122, 264942, 267783, 269176, and 276704) and
review of the literature [6-10,13-22], phenotypic and dele-
tion overlaps among individuals with monosomies span-
ning different sizes were delineated. We used the UCSC
Genome Browser Custom Track (http://genome-euro.ucsc.
edu/cgi-bin/hgCustom) to map these cases and targeted
the narrowest critical interval for CP, CHD, ID, and ASD.
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Classical and molecular cytogenetic analyses
Conventional chromosome banding analysis of the pro-
band revealed a 46,XY karyotype without gross abnormal-
ities. However, the distal G-band negative region in the
long arm of chromosome 4 corresponding to q35.1q35.2
appeared to be somewhat smaller in one of the homologs,
suggestive of a loss of chromosome material (Figure 1A).
Both parents had normal karyotypes without evidence of
deletion on chromosome 4q.
To validate the deletion in the proband, SNP array ana-
lysis was performed which disclosed a 6.9 Mb heterozy-
gous deletion on chromosome 4q35.1q35.2 (184,046,156-
190,901,117 bp from rs17074417 to rs10005101, hg19)
(Figure 1B). qPCR analysis of FRG1 exons 1, 8, and
DUX4L6 confirmed that the distal deletion breakpoint ex-
tends beyond 190,939,252 bp (data not shown), encom-
passing a total of 42 annotated genes (18 OMIM genes).
Based on these results, the proband’s karyotype could be
assigned as 46,XY,del(4)(q35.1q35.2). SNP array analyses
of maternal and paternal DNA did not indicate CNV for
chromosome 4q in the parental karyotypes, consistent
with a de novo deletion in the child. Informative SNPs
from the terminal 4q region for which the mother andFigure 1 Molecular karyotyping of the patient and his parents. (A) GT
proband, mother and father. The chromosomes are counterstained with DA
fluorescein-dUTP (green) and the deleted BAC RP11-775P18 with rhodamin
the patient’s derivative chromosome. (B) Illumina SNP array analysis (B allel
terminal 4q deletion syndrome. (C) Selected genotypes in the deletion inte
(middle), and father (right). Mendelian transmission errors (absence of matefather have divergent genotypes revealed a loss of mater-
nal genotypes in the child (Figure 1C), compatible with
maternal origin of the deleted chromosome.
FISH analysis was performed with BACs from the prox-
imal flanking region 4q35.1 (RP11-188P17) and the de-
leted region 4q35.1q35.2 (RP11-775P18, RP11-118M15,
and RP11-652J12). As expected, the flanking BAC probe
hybridized to both chromosomes in the proband and par-
ental metaphase spreads. Probes from the deleted region
recognized only one chromosome 4 homolog of the pa-
tient, but were present on both chromosome 4q35.1q35.2
copies of father and mother (Figure 1A). Obviously, the de
novo deletion is not due to a cytogenetically cryptic subte-
lomeric translocation in a parental karyotype.
Genotype-phenotype correlation of terminal 4q deletion
syndrome
We created a map of terminal 4q deletion syndrome cases
through reviewing the literature and DECIPHER database.
Figure 2 (upper section) presents 36 deletion cases (includ-
ing our own) meeting our interval criteria and after con-
trolling for normal CNV from the Database of Genomic
Variants (http://dgv.tcag.ca/dgv/app/home). Although we
had to estimate best fit intervals for cases describingG-banding and FISH analysis of homologous chromosomes 4 in
PI (blue). The proximal flanking BAC RP11-188P17 is labeled with
e-dUTP (red). An arrowhead indicates the critical band q35.1q35.2 on
e frequency and log R ratio) of the 4q35.1q35.2 region in the boy with
rval from the Illumina array are depicted for proband (left), mother
rnal genotypes) in the proband are indicated in gray.
Figure 2 Genotype-phenotype correlation of terminal 4q deletions. The upper part of the figure presents the mapped deletion intervals in
chromosome 4q31.1qter including the present case, marked with a box, and 35 additional cases from DECIPHER and the literature. The red bars
delineate the deletion region for each case. Highlighted intervals indicate critical regions for common phenotypes among the cases. Depicted,
from left to right, are the intervals for cleft palate (purple), congenital heart defect region 1 (light green), intellectual disability (dark green),
congenital heart defect region 2 (red), and autism spectrum disorder (turquoise). Orange indicates the mapping interval of the DFNA24 locus.
The middle section shows the gene content of the 4q31.1qter region. Likely disease-relevant genes overlapping with critical deletion intervals are
boxed. The bottom diagram shows the deCODE recombination map, highlighting male and female recombination hotspots in the terminal 4q
deletion syndrome region.
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able to roughly map out five critical regions for four
common 4q deletion syndrome phenotypes: CP, CHD,
ID, and ASD. Figure 2 (middle section) and Additional
file 1: Table S1 show the gene content of the deletion re-
gion, with an emphasis on genes implicated in the vari-
ous associated phenotypes. Additional file 2: Table S2details case summaries including approximate deletion
sizes, inheritance and phenotype information.
A locus (chr. 4: 155,600,001-158,373,133 bp) for CP
(Figure 2, purple) was mapped with two out of three cases
spanning this region having CP [7,10]. The gene PDGFC is
important for development of the palate with implication
in non-syndromic orofacial clefting [23]. Furthermore,
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under evaluation indicate CP, suggesting an additional crit-
ical interval involved in palate formation.
Congenital heart defects were mapped to two separate
regions. The first region (Figure 2, light green) spans a
large interval (chr. 4: 160,717,000-178,579,037 bp) unable
to be further subdivided based on the cases presented.
There are 17 cases with various cardiac phenotypes, 13 of
which overlap with the proposed interval, with three indi-
viduals unique to this first CHD locus [10,18,21]. This
interval contains two genes of interest (Additional file 1:
Table S1). TLL1 is important for mammalian heart sept-
ation [25]. Mice with abnormalities in this gene die from
blood circulation failure [26]. From mouse and zebrafish
experiments, HAND2 is also involved in cardiac morpho-
genesis, angiogenesis, and formation of the right ventricle
and aortic arch arteries and, interestingly, plays a role in
limb formation [27,28]. Although many individuals pre-
sented digital and forearm deficiencies, we were not able
to clearly map these phenotypes to this region as well.
The second CHD locus (chr. 4: 184,046,156-186,997,
806 bp) maps in a region containing 12 out of 17 over-
lapping cases with cardiac phenotypes (Figure 2, red),
two of whom uniquely overlap with this region. The crit-
ical interval contains two adjacent genes, PDLIM3 and
SORBS2, implicated in cardiac development. PDLIM3 is
essential for right ventricular development and thought
to enhance mechanical strength stability of cardiac
muscle during mouse development [29]. SORBS2 is
highly expressed in the intercalated disk in normal car-
diac tissue [30]. Additionally, SORBS2 could have impli-
cation in CP formation, since case #20 [9] with CP has a
small deletion (chr. 4: 186,533,075-186,997,806 bp) ex-
clusively affecting SORBS2 and TLR3 (Figure 2, upper
and middle section). Ten out of 13 total individuals with
CP overlapped with this region, but the proximal border
was too large to map an informative locus.
A smaller region (chr. 4: 171,144,641-175,897,427 bp)
within the first CHD interval may account for ID, with
eight of 15 individuals having ID (Figure 2, dark green).
While no gene is presently linked to ID in this region,
the gene SCRG1 is highly expressed in the brain and has
differential regulation in schizophrenia and bipolar dis-
order [31] (Additional file 1: Table S1). Lack of genomic
variation among healthy individuals in the Database of
Genomic Variants and strong evolutionary conservation
(data not shown) further emphasize the importance of
normal copy number of this ID region.
A number of reports implicate chromosome 4q35.2 in
ASD [20,22]. While only four cases reviewed here have
ASD (Additional file 2: Table S2), all four overlap one nar-
row interval (chr. 4: 187,234,067-188,424,639 bp) (Figure 2,
turquoise) with only three genes (MTNR1A, FAT1 and
F11), that was first reported in a boy with ASD [22]. FAT1has been associated with bipolar affective disorder [32]
and ASD [33], and is essential for controlling developmen-
tal cell proliferation [34].
Mild factor XI deficiency and elevated prothrombin
time in our proband are presumably explained through
deletion of F11 [35,36] and an adjacent coagulation gene,
KLKB1 [37]. Surprisingly, the mild bleeding tendencies
that can be associated with F11 and KLKB1 deletions have
not been discussed in great detail yet, although many
children with terminal 4q deletion syndrome require mul-
tiple surgeries.
The first clinical symptom of our patient with a 6.9 Mb
deletion (chr. 4: 184,046,156-190,901,117 bp) was mild to
severe bilateral hearing loss. Two additional cases with lar-
ger deletions, DECIPHER case 256186 and the case from
Calabrese et al., 1997 [16], also reported hearing impair-
ment. In a Swiss-German kindred with autosomal domin-
ant non-syndromic hearing loss, an autosomal dominant
deafness locus, DFNA24 (MIM: 606282) was mapped to
an 8.1 Mb region (chr. 4: 183,200,000-191,154,276 bp)
(Figure 2, orange) on chromosome 4q35qter [38,39]. How-
ever, in this context it is important to emphasize that 11
normal hearing terminal 4q deletion cases overlap com-
pletely and nine normal hearing cases overlap partially
with the DFNA24 interval. Thus, loss of one locus copy is
not sufficient to cause DFNA24. A cumulative effect of
rare, pathogenic variants in different deafness genes
scattered across the genome (i.e. haploinsufficiency for
DFNA24) could contribute to hearing impairment [40].
Mouse knockout experiments suggest that Casp3, which
is contained in the critical region, is required for proper
functioning of the cochlea [41-43]. Casp3−/− mice indi-
cated sensorineural hearing loss, whereas Casp3+/− mice
displayed intermediate vestibular dysfunction, as well as
marginally increased hair cell counts.
Discussion
Since its first description [44], the genotype-phenotype de-
lineation of chromosome 4q deletion syndrome has been
complicated by extensive inconsistencies reported among
individuals with similar deletion intervals. With >170
genes residing in the terminal 4q region, delineation of the
phenotypes associated with such deletions presents a tre-
mendous task toward understanding the complete spec-
tral presentation of a syndrome with excessive phenotypic
variability. The patient we present was analyzed with a
high resolution SNP array to delineate the deletion
interval and the parental origin of the de novo re-
arrangement. We found it especially challenging to
finely map disease-relevant intervals with the various
low-resolution techniques that used GTG banding
[7,10,13-15], FISH [16], and the different resolution ar-
rays, including BAC aCGH [18], 1 Mb aCGH [19], 44 K
aCGH [6,17,20], 105 K aCGH [9,22], and 300 K SNP
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tions in the depth of clinical descriptions listed, espe-
cially those from the DECIPHER database, which were
not as detailed as the published cases. Collectively, case-
supported critical regions for several distinct pheno-
types such as CP, CHD, ID, and ASD were defined. In
this context, it is important to emphasize that most
phenotypic features that are associated with terminal 4q
deletion syndrome show incomplete penetrance and/or
are rather unspecific, which renders genotype-phenotype
correlations difficult.
The overwhelming majority of cases are de novo pos-
sibly due to errors during meiotic recombination leading
to a loss of chromosomal material from one parental
allele. Meiotic crossovers preferentially occur at non-
random hotspots which have been mapped according to
frequency and spatial distribution in both males and fe-
males [45]. The deCODE recombination map [46] of the
4q31.1qter region illustrates an enrichment of both male
and female hotspots along the major part of this interval
(Figure 2, bottom section). However, it is also possible
that deletions arise in mitotically dividing spermatogon-
ial and oogonial stem cells, respectively. The resulting
germ-cell mosaicism would increase the likelihood of
having another child with the same deletion.
In summary, the case presented here is the first to use
a SNP array to determine the parent-of-origin of the
large deletion. Assuming that the same gene(s) is under-
lying hearing impairment in terminal 4q deletion and
DFNA24 patients, it may help further narrow the
DFNA24 locus. Our case, in combination with the cases
described in the literature and DECIPHER, accommo-
date a proposal of critical phenotypic intervals with pos-
sible genes of interest. This review is not intended as a
holistic description of terminal chromosome 4q deletion
syndrome. However, the ongoing reporting of precisely
defined deletion intervals with higher resolution tech-
nologies will support eventual refinement and possible
clarification of the genes and pathways responsible for
the broad phenotypic presentation of deletions in this
interval of chromosome 4q.Consent
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